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Letter to Editor
Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving
endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J
Bone Oncol 2019; 18:100252)
We read with great interest the systematic review and a meta-ana-
lysis of randomized trials on denosumab for bone health in cancer pa-
tients receiving endocrine therapy by Galvano A. et al. [1]. We disagree
with the main conclusion of this review article, which is that deno-
sumab administration can be considered effective and safe in this
clinical situation.
In prostate cancer patients receiving androgen deprivation therapy,
and in patients under adjuvant endocrine therapy for early-stage en-
docrine-sensitive breast cancer, denosumab is routinely discontinued
when the hormonal treatment is interrupted, unless a diagnosis of os-
teoporosis persists. It is now well known that denosumab discontinua-
tion is associated with a severe rebound effect that lasts 2 years, which
combines an increase in bone turnover markers and a complete loss of
the gained bone density [2]. This rebound effect is associated, in post-
menopausal osteoporosis, with multiple spontaneous vertebral fractures
(MSVF) as described in several case series and in the post-hoc follow-up
of the pivotal FREEDOM trial [3–7]. Cases have also been described in
men [8]. It is a severe secondary effect, as patients present a median of
five (1–11) vertebral fractures 7–20 months (median 11) after the last
denosumab injection [7]. 1–10% of women with post-menopausal os-
teoporosis discontinuing denosumab suffer of MSVF, and although bi-
sphosphonates given at denosumab discontinuation probably decrease
the MVSF risk, cases of fracture despite bisphosphonate treatment have
been described [7].
One could think that patients receiving denosumab for bone health
preservation during hormonal therapies designed for breast and pros-
tate tumors with a low fracture risk might be protected from MVSF. No
case has been described including patients with prostate tumors under
hormonal treatment. However, unpublished data from the off-treatment
follow-up of the ABCSG-18 trial suggests the risk is increased similarly
to post-menopausal women in those treated with aromatase-inhibitors
[9]: in this study, the hazard ratio for MSFV was 3.52 (CI 0.98, 12.64)
in women who stopped denosumab as compared to women who
stopped placebo. Indeed, we just published data on a cohort of 15
women with early-stage breast cancer treated with aromatase inhibitors
and denosumab for bone loss prevention [10]: they suffered 1–11
(mean 4.0 ± 1.9) clinical vertebral fractures within 7–16 months after
last denosumab injection. Importantly, these fractures appeared earlier
in patients without osteoporosis before denosumab (9.4 ± 2.0 vs.
13.0 ± 2.0 months; p = 0.005), suggesting low fracture risk does not
protect from this adverse event.
We are aware that there is no published data on denosumab dis-
continuation in the targeted population to be included in the meta-
analysis. However, this risk should be discussed, and the absence of off-
denosumab solid data cited as an important limitation of the study, as
the safety profile should also consider the significant post-treatment
events.
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